Sugammadex Injection, Solution
Product Images NDC 67457-969

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Sugammadex (NDC 67457-969). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Mylan Institutional Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Sugammadex Injection 200 mg/2 mL Carton Label (Image 01)

Sugammadex Injection 200 mg/2 mL Carton Label (Image 01)
Packaging label for Sugammadex Injection 200 mg/2 mL (100 mg/mL) solution for intravenous use. The label indicates it contains 10 single-dose vials of 2 mL each. The labeler is Mylan Institutional LLC, with packaging by Viatris. It includes dosage, storage, and usage instructions, and features the NDC 67457-969-02.*
FDA Label Image

Sugammadex Injection 500 mg/5 mL Carton Label (Image 02)

Sugammadex Injection 500 mg/5 mL Carton Label (Image 02)
Packaging label for Sugammadex injection, 500 mg/5 mL (100 mg/mL) solution for intravenous use. The label indicates it is supplied as 10 single-dose 5 mL vials. The labeler is Mylan Institutional LLC, with distribution by Viatris. It specifies Rx only and instructs to discard unused portions.*
FDA Label Image

Sugammadex Sodium Structural Formula (Image 03)

Sugammadex Sodium Structural Formula (Image 03)
Chemical structure of sugammadex showing its molecular arrangement with multiple sodium carboxylate groups and sulfur atoms in a cyclic configuration.*
FDA Label Image

Mono Oh-derivative Of Sugammadex Structural Formula (Image 04)

Mono Oh-derivative Of Sugammadex Structural Formula (Image 04)
Chemical structure diagram of Sugammadex, showing its cyclic molecular arrangement with hydroxyl, sodium carboxylate, and sulfur atoms represented in a detailed 2D format.*
FDA Label Image

Figure 1: Time (minutes) From Administration Of Sugammadex Or Neostigmine At The Reappearance Of T2 After Rocuronium To Recovery Of The T4/t1 Ratio To 0.9 (Image 05)

Figure 1: Time (minutes) From Administration Of Sugammadex Or Neostigmine At The Reappearance Of T2 After Rocuronium To Recovery Of The T4/t1 Ratio To 0.9 (Image 05)
A cumulative recovery rate graph comparing Sugammadex 2 mg/kg and Neostigmine 0.05 mg/kg over time. The x-axis shows time to recovery in minutes (0 to 120), and the y-axis shows cumulative recovery rate (0 to 1.0). The graph indicates faster recovery for Sugammadex compared to Neostigmine, with median recovery times of 1.4 minutes and 21.5 minutes respectively.*
FDA Label Image

Figure 2: Time (minutes) From Administration Of Sugammadex Or Neostigmine At The Reappearance Of T2 After Vecuronium To Recovery Of The T4/t1 Ratio To 0.9 (Image 06)

Figure 2: Time (minutes) From Administration Of Sugammadex Or Neostigmine At The Reappearance Of T2 After Vecuronium To Recovery Of The T4/t1 Ratio To 0.9 (Image 06)
A cumulative recovery rate chart showing the time to recovery in minutes on the x-axis and cumulative recovery rate on the y-axis. The graph compares two treatments, sugammadex 2 mg/kg and neostigmine 0.05 mg/kg, with sugammadex showing a faster recovery time. Median recovery times are noted as 2.1 minutes for sugammadex and 29.0 minutes for neostigmine. Censored observations and quartiles are also indicated.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.